gefacixant

gefapixant · Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for gefacixant, covering 2017-03-17 to 2017-03-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

See pricing